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Abstract
Background Multimorbidity and polypharmacy represent
a major problem for elderly patients; improvement of
medication schemes is important and listing approaches
(e.g. Beers list) are considered to be potentially useful.
Objectives The aim of this study was to perform expert
consensus validation of the FORTA (Fit fOR The Aged)
List, a drug classification combining positive and negative
labelling of drugs chronically prescribed to elderly patients.
Methods A two-round Delphi procedure was conducted
involving 20 experts, 17 geriatric internists and 3 geriatric
psychiatrists from Germany and Austria, evaluating the
labels assigned to 190 substances or substance groups.
These labels ranged from A (indispensable), B (beneficial),
C (questionable) to D (avoid), depending on the state of
evidence for safety, efficacy and overall age-appropriate-
ness. The experts were also requested to suggest additional
substances and indication areas for assessment and possible
inclusion in the FORTA List. A weighted (corrected)
consensus coefficient was generated for each substance to
reflect (1) agreement with the original label, and (2) dis-
tribution among raters’ labels.
Results The overall consensus for all items and raters was
92 % (corrected). For 54/190 items (28.4 %), a unanimous
response was achieved as to the original author-based
FORTA label choice. Twenty-four substances (12.6 %) fell
short of the consensus cutoff and were re-evaluated in a
second round. This yielded confirmation of 171/190, or
90 %, of the original author-based FORTA labels. A total
of 35 new substances were also accepted for the FORTA
List. Drugs used for dementia and dementia syndromes
provoked particular response heterogeneity.
Conclusion The FORTA List now reflects a wider con-
sensus among experts, increasing its validity for clinical
use. It represents a tool to improve the quality of drug
prescription in older patients by identifying both inappro-
priate and omitted drugs, and thus overtreatment and
undertreatment. The validation of FORTA’s impact on
clinical endpoints has yielded promising preliminary
results, to be corroborated in ongoing larger trials.
1 Introduction
The increase in life expectancy is triggering dramatic
demographic changes in industrialized countries. Figures
for 2010 provided by the US Census Bureau [1] indicate
that the population aged 65 years and older has increased
over the past decade from 35.0 million in 2000 to 40.3
million in 2010, representing 13.0 % of the total popula-
tion. In Germany, this percentage is at 20 % for 2009 [2].
Elderly multimorbid patients are more likely to receive
multiple drug treatments (polypharmacy) compared with
younger patients. It has been demonstrated that patients
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aged 65 years and older take five or more drugs in 44 %
(male) and 57 % (female) of cases, and ten or more drugs
in 12 % of cases [3]. Each medical guideline recommends
an average of three medications. According to figures from
1998, persons over 80 years of age have an average of
three diagnoses; this means 3 9 3 = 9 medications in
elderly patients, which is also reflected in real life [4].
Multimorbidity and polypharmacy often harbour
unpredictable dangers due to age-related alterations in
pharmacokinetics and pharmacodynamics [5], adverse drug
reactions [6], which may trigger the so-called prescribing
cascade [7], drug–drug or drug–disease interactions,
problems with dosages, medication errors, and even death
[8]. This translates, for example, into approximately 2.1
million side effect-related hospital admissions and 100,000
deaths per year in the US, out of a total population of 265
million inhabitants, and costs of approximately 1.5–4 bil-
lion dollars per year [9]. The risk of potential drug inter-
actions necessarily increases with the number of drugs
prescribed [10].
Geriatric medicine is a rapidly growing discipline in the
Western world [11, 12]. The paucity of evidence-based
guidelines and clinical studies for the elderly is alarming
and contributes to the challenges of rationalistic drug pre-
scribing in elderly patients. Many elderly persons display
limitations in their physical and mental capacities [13],
nearly always precluding their inclusion in clinical drug
trials. The sometimes rigid adherence to available guide-
lines presents another significant problem as there are
virtually no evidence-based guidelines for this very heter-
ogeneous group; the underlying assumption ‘one guideline
fits all’ simply does not work in this age bracket [14].
These limitations necessitate the development of criteria or
concepts for safer and more efficient drug use in the
elderly, ideally amalgamated at an international level.
In response to these challenges, many countries have
begun to develop strategies for the safer prescribing of
medications in elderly patients [15]. A precedent was set
by the Beers Criteria [16] which classify potentially inap-
propriate medications (PIMs) according to three categories
describing the degree of inappropriateness; this listing has
undergone several updates, recently winning the support of
the American Geriatric Society [17]. The German coun-
terpart, the PRISCUS (PIM) List, was published in 2010
[18]. Such ‘negative lists’ have proven to be quite practi-
cable, but still lack confirmation as to effectiveness at the
clinical endpoint level [19].
Gallagher et al. introduced the STOPP (Screening Tool
of Older Persons’ Prescriptions)/START (Screening Tool
to Alert Doctors to the Right Treatment) Criteria in 2008
[20]. The STOPP criteria allow the detection of potential
overtreatment and place a special emphasis on drug–
disease interactions; the START criteria serve to assist the
physician in targeting potential errors of omission by pin-
pointing treatments that may be indicated but not pre-
scribed [21]. It has been suggested in the literature that the
STOPP criteria may have a higher sensitivity than the
Beers criteria for detecting PIMs [22].
The FORTA (Fit fOR The Aged) classification system
was proposed in 2008 [23, 24] as a tool for aiding physi-
cians from participating countries (initially Germany) in
screening for unnecessary, inappropriate or harmful medi-
cations and drug omissions in older patients in an everyday
clinical setting. It is the first classification system in which
both negative and positive labelling are combined at the
level of individual drugs or drug groups. As it aims at the
individual indications (implicit listing requiring patient
characteristics/diagnoses) it is thus clearly different from
negative lists which focus on major problems in drug pre-
scribing (errors of commission or omission, or risky medi-
cations within all frequently used drug classes) that should
rather be avoided when prescribing to geriatric patients
because of age-related changes (explicit lists largely inde-
pendent of individual patient characteristics). FORTA is
evidence-based and real-life oriented. Factors such as
adherence issues, age-dependent tolerance and frequency of
relative contraindications are given due consideration since
strict and citable evidence, as typically derived from ran-
domized clinical trials, is still rare for this population,
although important if available. A medication can receive
different FORTA labels for different indications (indica-
tion-dependent). FORTA does not take the place of indi-
vidual therapeutic considerations or decisions.
Contraindications always take precedence over the FORTA-
classification. The system does allow for exceptions.
The FORTA classes are defined as follows:
• Class A (A-bsolutely) = indispensable drug, clear-cut
benefit in terms of efficacy/safety ratio proven in
elderly patients for a given indication
• Class B (B-eneficial) = drugs with proven or obvious
efficacy in the elderly, but limited extent of effect or
safety concerns
• Class C (C-areful) = drugs with questionable efficacy/
safety profiles in the elderly, to be avoided or omitted in
the presence of too many drugs, lack of benefits or
emerging side effects; review/find alternatives
• Class D (D-on’t) = avoid in the elderly, omit first,
review/find alternatives
The FORTA List is a compilation of 190 medications
(primarily long-term treatment, exceptions are noted) [25]
most frequently prescribed in older patients, aligned to 20
main indication groups. Each substance or group is assigned
a FORTA class A, B, C or D. In cases in which homogeneity
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was considered to be high and of lesser significance with
respect to other aspects of the group of drugs concerning
age-related issues, similar drugs were grouped and assessed
as such (angiotensin-converting enzyme [ACE] inhibitors
as an example). If individual compounds were considered to
be heterogenous, rating was performed for individual drugs
(acetylsalicylic acid, clopidogrel—although both are con-
sidered as platelet inhibitors). This original version of the
FORTA list is part of reference [25] and was created by the
book authors, including the original author of the method.
The rating was opinion-based by an integrative approach
which comprised available study evidence as cited in the
book. It thus was also evidence-based where such evidence
was available. Although exact-use data are as yet missing,
the original FORTA list is increasingly recognized in Ger-
many, as suggested by the fact that the 3rd edition of the
seminal book (2013) had to be published within 3 years
after the first (2010); for this survey, the 2nd edition (2011)
was relevant [25].
Our aims, within the context of a two-round Delphi
Consensus procedure, included the rater-based confirma-
tion/determination of labels for 190 items in the original
author-based FORTA List, and identification and labeling
of new indications/substances. As a consensus-based
approach this process reflects the rating of many experts,
drawing on both available evidence and personal experi-
ence/opinion.
The consensus validation of the FORTA List represents
the first phase of a two-part development programme
funded by the German Research Foundation; a clinical
study is running to test the impact of the FORTA system on
the quality of pharmacotherapy and clinical endpoints in
400 patients from two German geriatric clinics by imple-
menting the FORTA List.
2 Methods
The consensus validation procedure included
1. Review of the available literature and examples of
practical applications of the Delphi method.
2. Recruitment of experts in the German-speaking coun-
tries (Germany, Austria and Switzerland) representing
geriatric internists/geriatricians and geriatric psychia-
trists with extensive clinical experience in the phar-
macotherapy of (multimorbid) elderly patients; high
academic status; prominent standing in the leading
geriatric/psychiatric medical associations; and number,
quality and relevance of experts’ publications. The
selection was based on available information on the
Internet in an iterative, semi-quantitative process by
two of the authors (AKT and MW).
3. Round 1: The FORTA List was adapted from its
original publication form [25] to a questionnaire and
sent to the experts via e-mail (see original survey as
Electronic Supplementary Material [ESM] 2). Partic-
ipants were requested to review the instructions on
how to apply the FORTA principle; study the author-
based labels (A–D) for each item and provide their
own FORTA labels (or abstention) whenever in
disagreement; and make comments. In a separate
section, the experts were requested to suggest new
substances/indications with labels, to augment the
FORTA List. All experts had been exposed to the
related book [25] as the common, although certainly
not exclusive, base of evidence compiled from the
literature.
4. Statistical analysis based on Round 1 input was
performed as follows: the Likert scale is often
favoured for consensus procedures, as well as means,
median and mode (‘central tendency’ indicators) [26,
27]. For evaluating the FORTA labelling system, we
adapted the Likert scale with the aim of devising an
algorithm combining collective/central tendency
regarding the original labels with impact of distribu-
tion/dispersion of raters’ labels. To achieve this, the
percentage of raters’ labels (excluding abstentions)
agreeing with the original author-based labels was
calculated, both overall and for each item separately.
The resulting percentages were then weighted to
generate a corrected consensus coefficient (cons_corr,
definition see ESM 1, FORTA list, p. 41) for each item
reflecting the degrees of deviation between the experts’
individual FORTA ratings. Although at first glance
seemingly arbitrary, those weighing factors appear, for
our purposes, plausible [28–30]. This ultimately allows
the actual assignment of FORTA class values to the
substances in question. The weighting system, reflect-
ing degrees of deviation, was expressed in terms of
range class (Table 1), defined as:
• Range 0: unanimity among all experts giving a
FORTA rating (no deviation);
• Range 1: greatest range only from A to B, B to C
or C to D (neighbouring classes), half weight;
Table 1 Frequency of substances in defined range groups according
to degree of consensus
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• Range 2: greatest distance from A to C or B to D,
two-thirds weight;
• Range 3: greatest distance from A to D, full weight.
In order to confirm the original/determine new, rater-
based labels, we converted the experts’ FORTA
ratings into numerical values representing the median:
A ? 1, B ? 2, C ? 3 and D ? 4, respectively. The
mean and mode were calculated for each item,
reconverted to FORTA labels and compared with the
original author-based labels. The range for each label
was defined as:
If 1 B m \ 1.5 ? FORTA Class A
If 1.5 B m \ 2.5 ? FORTA Class B
If 2.5 B m \ 3.5 ? FORTA Class C
If m C 3.5 ? FORTA Class AD
where m = arithmetic mean based on the raters’
grades 1–4.
The scale has not been defined in order to allow for
complex statistical calculations. The purpose of this
scale was to pool the judgements by taking into
account each rater judgement. This was necessary to
enable a comparison to be made between the raters’
opinions and the FORTA classifications. The assign-
ment of A ? 1, B ? 2, C ? 3 and D ? 4 seems to
be plausible when assuming that any difference (1–2,
2–3, 3–4) is equally important [31].
5. Round 2: Substances falling short of the preset
corrected consensus cutoff of 0.800 were re-sent to
the experts. New substances suggested by C2 raters
and all new indications were sent to the experts for
evaluation in the form of a questionnaire.
6. Analysis based on Round 2 input was performed as
follows: confirmation of FORTA labels/determination
of new rater-based FORTA labels for re-evaluated
items derived from the arithmetic mean (as described
above); review of all comments. A simple ‘agree–
disagree’ approach or 5-point scale was not chosen;
quantification of disagreement seemed necessary as
there are four categories of answers (FORTA classes),
and a full match is unlikely to occur; thus, this approach
may possibly have led to an equally large second round.
In this way, the actual FORTA classes could be
preserved as such and either confirmed or challenged.
7. Compilation of an annotated FORTA List based on
experts’ input over two rounds.
The substances and indications suggested by the experts
were selected as follows:
1. Acceptance of all substances/indications receiving an
affirmative response by [50 % of experts during
Round 2 and receiving a FORTA rating (excluding
abstentions) by C8 raters.
2. Calculation of a kappa index reflecting label disper-
sion: here, kappa is defined as the (proportion of
‘matching’ labels - 0.25)/0.75. This gives due con-
sideration to the fact that a figure of 25 % can
theoretically be attained by chance alone, with the
choice of four distinct labels.
3. Conversion to median and calculation of mean and
mode, as in the first procedure. The arithmetic mean
provided the basis for conversion to FORTA labels.
4. Compilation of all substances in a separate, annotated
list.
3 Results
Twenty experts, 17 geriatric internists and three geriatric
psychiatrists representing Germany (13) and Austria (7)
agreed to participate in the survey. The return rate for both
rounds was 100 %.
The overall consensus for all items and experts after
Round 1 was found to be 92 %, corrected (mean 0.922,
median 0.950, range 0.500–1.000). Overall, 54/190
(28.4 %) of the evaluated items elicited unanimous
agreement among the raters (Table 1) and 24/190 (12.6 %)
items fell short of the cutoff of 0.800 and were re-evaluated
in a second round (Table 2). Of these 24 items, 19 (79.2 %)
represented substances commonly used for the prevention
or treatment of dementia and dementia syndromes; 3/24
substances (12.5 %) represented drugs used for treating
cardiovascular diseases; 1/24 (4.2 %) was a drug pre-
scribed for depression and 1/24 (4.2 %) for osteoporosis.
Backed by experts’ largely convergent comments on the
individual substances, two consistent trends could thus be
detected. These indicated a shift in the FORTA labels for
drugs used to prevent or treat dementia and dementia
syndromes:
1. Agreement with the original C label for substances
administered for dementia was observed in most cases
for the participating geriatric psychiatrists, as opposed
to geriatric internists, who tended to favour the D label
in these cases. In future FORTA developments, this
area should be rated by a larger group of geriatric
psychiatrists to emphasize their particular experience
in this area.
2. The original D label was challenged specifically for
neuroleptic drugs by both geriatric psychiatrists and
geriatric internists; many experts tended towards C and
expressed the wish for further differentiation/qualify-
ing statements pertaining to the therapy of behavioural
and psychological symptoms of dementia (BPSD).
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Round 1 Round 1 (cutoff
0.800)
Round 1
Round 2 Round 2 mean; mode
Drugs to prevent or treat dementia or dementia-related syndromes
Nimodipine (C) Dementia 20 0.750 3.5; 3 D
19 3.7; 4




Dementia 20 0.725 3.6; 4 D
20 3.8; 4
Hormone preparations, e.g. DHEA
(C)
Dementia 20 0.700 3.6; 4 D
20 3.9; 4
Gingko biloba (C) Dementia 20 0.775 3.5; 3 D
20 3.6; 4
Ergoline derivatives (C) Dementia 19 0.763 3.5; 3 D
20 3.8; 4
Piracetam (C) Dementia 20 0.800 3.4; 3 D
20 3.6; 4
Pyritinol (C) Dementia 18 0.778 3.4; 3 D
19 3.7; 4
Selegiline (C) Dementia 19 0.763 3.5; 3 D
20 3.7; 4
Haloperidol (D) BPSD paranoia,
hallucinations
19 0.632 3.3; 4 C
20 3.0; 3
Risperidone (D) BPSD paranoia,
hallucinations
20 0.500 3.0; 2 C
20 2.7; 2
Quetiapine (D) BPSD paranoia,
hallucinations
20 0.575 3.2; 4 C
20 2.9; 3
Aripiprazole (D) [2–15 mg/day] BPSD paranoia,
hallucinations
19 0.789 3.6; 4 C
17 3.4; 4
Clozapine (D) [10–50 mg/day] BPSD paranoia,
hallucinations
20 0.800 3.6; 4 D
19 3.7; 4
Risperidone (D) BPSD restlessness 20 0.625 3.3; 4 C
20 2.7; 2
Melperone (D) BPSD restlessness 20 0.675 3.4; 4 C
20 3.4; 4
Quetiapine (D) [25–200 mg/day] BPSD restlessness 19 0.763 3.5; 4 C
19 3.3; 3
Pipamperone (D) [20–150 mg/day] BPSD restlessness 19 0.790 3.6; 4 D
17 3.6; 4
Mirtazapine (C) [15–30 mg] BPSD sleep
disorders
20 0.775 3.0; 3 C
20 3.0; 3
Mirtazapine (D) Insomnia 20 0.700 3.4; 4 C
20 3.45; 4
Other drugs
Digitoxin (D) Atrial fibrillation 20 0.525 3.1; 4 C
19 2.5; 2
Digoxin (B) Atrial fibrillation 20 0.800 2.4; 2 B
19 2.4; 2
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Due to abstentions, the number of raters varied for each
item (maximum 20, range 5–20). According to the raters’
comments, the most common reason for abstaining was
insufficient experience with a particular substance or
indication group and, in individual cases, potential conflict
of interest.
The indication area of oncological/haematological ill-
nesses (27 items) received the most abstentions and thus
the lowest number of raters (mean 7.41, median 7.22, range
5–12), yet the calculated corrected consensus values were
consistently high (mean 0.964, range 0.857–1.000) for all
items tested. Most experts gave the reason for abstention as
insufficient experience or lack of familiarity with the cur-
rent state of evidence for oncological treatments. One rater
documented a consultation with other experts in the field of
oncology. Re-evaluation was foregone, but this indication
group will be kept under close scrutiny during further
clinical development.
According to the calculations based on a numerical scale
for purposes of comparing the rater-based labels to the
original author-based labels, it was found that, after Round
1, 12 of the 24 re-evaluated items (6.3 % of the original
190 substances) had received a FORTA label diverging
from the original label. These 12 items correlated directly
with the substances receiving the lowest corrected con-
sensus coefficients. After Round 2, this number had
increased to 19 of the 24 retested substances (5/24 labels
confirmed), eliciting final confirmation of 90 % (171/190)
of the original labels. This increase in label deviation
appears to indicate that other factors may have played a
prominent role in the decision-making process for labelling
during Round 2.
A total of 35 new substances were accepted for potential
incorporation into the FORTA List. Nineteen substances
were included in four new indication areas: epilepsy (12),
anaemia (4), gastrointestinal illnesses/concomitant appli-
cation of non-steroidal anti-inflammatory drugs [NSAIDs]
(2) and bipolar disorder (1). Thus, the original opinion-
based proposal of indication areas by the authors of ref-
erence [25] was largely confirmed by the rater panel.
Sixteen substances associated with pre-existing FORTA
indications were included: drugs for the therapy of
depression (6), chronic pain (3), atrial fibrillation (2),
arterial hypertension (2), coronary heart disease (1), oste-
oporosis (1) and insomnia (1).
These results are summarized in the FORTA List,
available online as ESM 1 (full statistical details including
all results from the first round are available upon request).
4 Discussion
The Delphi method often presents a challenge to carry out
in practice, not least due to the lack of evidence in the
literature as to optimal standard operation procedures and
forms of interpretation. Nevertheless, it has become an
acceptable mode, and sometimes the only feasible option,
of obtaining experts’ opinions on particularly complex
topics [27, 32, 33].
Medication lists and classification systems developed
during the past few decades represent a variation on an
established theme. In the Comprehensive Drug Abuse and
Control Act of 1970, for example, harmful or habit-form-
ing drugs were ranked according to their ‘dangerousness’;
selected drugs were assigned to ‘specific … categories with
appropriate restrictions’ [34]. Our proposed FORTA sys-
tem involves the evidence-based classification of medica-
















Round 1 Round 1 (cutoff
0.800)
Round 1
Round 2 Round 2 mean; mode
Dronedarone (B) Atrial fibrillation 18 0.556 2.9; 3 C
18 3.0; 3
Strontium ranelate (B) Osteoporosis 17 0.794 2.1; 2 B
18 2.1; 2
FORTA Fit fOR The Aged, DHEA dehydroepiandrosterone, BPSD behavioural and psychological symptoms of dementia
a
A ! 1; B ! 2
C ! 3; D ! 4
If 1m\1:5 ! A
If 1:5m\2:5 ! B
If 2:5m\3:5 ! C
If m 3:5 ! D
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validation procedure, the FORTA List, a drug-appropri-
ateness rating system, has been endorsed and improved by
the input of 20 experts, thereby enhancing its value for
implementation in a clinical setting, while areas requiring
further attention and development clearly came into view.
The panel was chosen from clinical specialties only as
clinical experiences in the elderly appeared to be most
valuable in this patient population, which affected deci-
sions made as to the choice of inclusion of other specialties
(e.g. pharmacoepidemiology, pharmacists).
The still relatively tenuous or inconsistent state of evi-
dence associated with medications for dementia is also
reflected in examples from the literature [35–37]. This area
would appear to require further observation and develop-
ment during clinical studies. Future clinical projects will
also specifically have to target the problem of how best to
classify dementia in the FORTA List. Many experts dis-
cussed possible benefits of classification according to eti-
ology (i.e. Alzheimer’s vs. vascular origin). The FORTA
List divides dementia into subclasses according to addi-
tional syndromes (BPSD); drug therapy is either of pre-
ventive nature or symptom-oriented and has been
simplified here to the greatest extent possible. More spe-
cific differentiation during further clinical studies may
improve the overall quality and practicability of the
system.
The first positive indications of FORTA’s potential
usefulness in everyday clinical routine are apparent in
results obtained from a pilot study applying the FORTA
principle [38] to the drug therapy of 46 patients in a geri-
atric clinic in Essen, Germany. It could be demonstrated
that the number of Class A and B medications significantly
increased, and the number of Class C and D medications
were reduced. Preliminary data obtained from a prospec-
tive, single blinded, randomized trial involving 97 patients,
also conducted in Essen, further revealed that use of
FORTA may be associated with a reduction in in-hospital
falls [39].
Further-reaching applications of the FORTA system may
include refining the process of defining and assigning
FORTA labels (classes A–D) to newly selected and already-
established drugs assessed by Health Technology Assess-
ment institutions [for example, the National Institute for
Health and Care Excellence (NICE) in England, or the
Institut fu¨r Qualita¨t und Wirtschaftlichkeit im Gesundheit-
swesen (IQWiG, Institute for Quality and Economic
Effectiveness in Health Care in Germany)]. Although as yet
lacking in most major situations, future input provided by
controlled and, ultimately, real-life studies represent
equally essential components of the development procedure
for this drug labelling system, since adherence factors,
availability and application issues also play important roles
in determining the ultimate effectiveness and safety of these
substances [40]. Another future task is the further differ-
entiation and separation of distinct compounds that now
reside in a ‘mixed pot’, e.g. the group of ‘frequency-low-
ering b-blockers’ (FORTA list, p. 11), which formally still
contains sotalol but which is now considered mainly as a
class III antiarrhythmic (D drug), or propranolol, which
should not be used (with exceptions) for pharmacokinetic
reasons. For treatment of heart failure with b-blockers,
positively labelled compounds are listed (p. 10). Similarly,
not all dihydropyridines are well studied in the elderly, and
amlodipine is given as a lead example in the FORTA list (p.
9), reflecting the results of the Avoiding Cardiovascular
Events in Combination Therapy in Patients Living with
Systolic Hypertension (ACCOMPLISH) and Anglo-Scan-
dinavian Cardiac Outcomes Trial (ASCOT) trials [41, 42].
Nor are diuretics further differentiated, although long-term
data are mainly available for thiazides, e.g. in ACCOM-
PLISH. The choice between loop and thiazide diuretics is
guided by renal function and/or severity of heart failure, but
does not lead to different assessments as yet, mainly due to
the similarity in side effects (e.g. electrolyte disorders).
If compared with START/STOPP criteria, drugs rec-
ommended by START seem to belong predominantly to
FORTA classes A or B. Examples include statins or ace-
tylsalicylic acid in the treatment of coronary heart disease,
ACE inhibitors for heart failure, levodopa for Parkinson’s
disease, or corticosteroids and inhaled b2-agonists in
chronic obstructive pulmonary disease. Substances men-
tioned in the STOPP list [20] appear to correspond with
categories C and D as assigned by the FORTA system (see
also revised FORTA List). Here, examples include ben-
zodiazepines—unanimously voted across all systems to be
potentially inappropriate or negatively rated, either in
drug–disease connection or in and of themselves [17, 18,
20, 25, 43]—neuroleptic drugs, first-generation antihista-
mines or theophylline as monotherapy in chronic obstruc-
tive pulmonary disease.
Not unexpectedly for consensus processes, a few dis-
crepancies with the updated Beers list are also present.
Although difficult to compare directly, as individual sub-
stances are taken into consideration in relation to specific
illnesses or conditions (drug–disease aspect) [17, 43], one
notable example here includes the classification or use/non-
use of digoxin, which is listed to be avoided in higher
dosages. Concordance between Beers and FORTA is
however high; specific examples include the mention of
NSAIDs to be avoided in chronic use, doxazosin to avoid
as an antihypertensive, benzodiazepines and zolpidem to
avoid in most instances, and carbamazepine to be used with
caution, corresponding to the FORTA classes C and D for
these selected substances.
Compared to the PRISCUS list, most PIMs have been
labelled C or D, with few exceptions, most notably digoxin,
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as already mentioned above (FORTA B, PIM in PRISCUS,
Beers and STOPP) [17, 18, 20, 43]. This compound and its
congener, digitoxin, are on the list with major discrepan-
cies in ratings (Table 2); digoxin was rated favourably in
the treatment of atrial fibrillation as renal dosing is ame-
nable and intoxication effects are much shorter than for
digitoxin, still prescribed in Germany and rated FORTA C.
A major advance made by development of the FORTA
system has led to the quantitative assessment allowing for
cross-therapeutic prioritization and reflection of multiple
diseases leading to reduced medication schemes, whereas
START/STOPP criteria could still lead to additive poly-
pharmacy if multiple conditions are met. The user is
introduced to a standard, reproducible system, the repeated
employment of which may encourage an overall learning
effect (‘geriatric pharmacology in a nutshell’).
The ‘internationalization’ of the FORTA List may be
viewed as one of the next important steps in the develop-
ment of FORTA. In this context it is important to
acknowledge that most PIM lists and clinical tools do
remain country-specific, both in Europe (most European
countries such as Germany, France, Norway and Austria
have their own negative listings) and in the US (Beers
List). This reflects the diversity of national drug use and
regulatory status. It may however be noted that the original
authors did not encounter any major problems converting
to the US system, as documented in the first English-lan-
guage edition of the original FORTA source containing the
author-based, US version of the FORTA List [44].
Although not developed for European countries, the Beers
and McLeod lists from the US and Canada, respectively,
have been successfully used to detect and compare PIMs in
eight European countries [45]. Thus, drug listing approa-
ches seem to be principally applicable even to geographi-
cally removed industrialized societies. Yet, the well-known
potential obstacles of divergence and differences in drug
availability, as well as country-specific prescribing trends,
demography and disease epidemiology must not be
ignored. Thus, ensuing ‘gaps’ or inconsistencies, while not
actively presenting a hindrance in our estimation, still
represent an area requiring intensified cooperative efforts,
ideally on an international level.
5 Limitations of the Survey
Important limitations of the Delphi process which arose
and should be mentioned here include the following issues:
1. The choice of raters did not include a wide array of
experts, e.g. general practitioners for ambulatory care,
pharmacists or higher numbers of geriatric psychiatrists.
2. The FORTA List may have limited applicability for
international use and still awaits adaptations in an
internationalization process.
3. There is a relative lack of evidence-driven ratings
compared with consensus-driven ratings. Future modifi-
cations should emphasize evidence-driven ratings, par-
ticularly in emerging areas of age-related therapeutic
knowledge or innovations, e.g. novel oral anticoagulants.
4. Due to the emphasis on implicit criteria (the individual
patient has to be considered for the application of the
FORTA List) the utility of theFORTA toolmay be limited
regarding its use in pharmacoepidemiological research.
5. FORTA does not specifically address drug–drug
interactions or contraindications which still need to
be checked individually, as well as drug doses and
medication scheduling; it does not aim at detecting
prescribing cascades, although an increased quality of
prescriptions will certainly help to reduce them.
6 Conclusion
When applied according to specific, well-defined criteria
within the context of individualized patient care and
management, the FORTA List should help physicians to
optimize drug treatment in their older patients. The expert
consensus validation process for the FORTA List was
essential in its development, and it is our hope that this will
ultimately facilitate its use in clinical practice.
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Appendix
Original FORTA List Authors[25] and Their Affiliations
Martin Wehling, MD: Institute for Experimental and
Clinical Pharmacology and Toxicology, Department of
Clinical Pharmacology, Center for Geriatric Pharmacology,
Medical Faculty Mannheim, University of Heidelberg,
Maybachstr. 14, 68169 Mannheim, Germany
Heinrich Burkhardt, MD: University Medical Centre
Mannheim, 4th Department of Medicine, Geriatric Medi-
cine, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
Lutz Fro¨lich, MD: Central Institute of Mental Health, J5,
68159 Mannheim, Germany
Stefan Schwarz, MD: Central Institute of Mental Health,
J5, 68159 Mannheim, Germany
Ulrich Wedding, MD: University Hospital, Clinic for
Internal Medicine II, Erlanger Allee 101, 07747 Jena, Germany
Expert Panel Members and Their Affiliations
Ju¨rgen Bauer, MD: Geriatrics Centre Oldenburg, Uni-
versity of Oldenburg, Rahel-Straus-Straße 10, 26133 Old-
enburg, Germany
Heiner K. Berthold, MD: Charite´ University Medicine
Berlin, Evangelical Geriatrics Center Berlin (EGZB), Re-
inickendorfer Str. 61, 13347 Berlin, Germany
Peter Dovjak, MD: Gmunden Hospital, Department of
Acute Geriatric Medicine, Miller-von-Aichholz-Straße 49,
A-4810 Gmunden, Austria
Helmut Frohnhofen, MD: Essen-Mitte Hospital, Knap-
pschafts Hospital, Teaching Hospital, University of Duis-
burg-Essen, Am Deimelsberg 34a, 45276 Essen, Germany,
and Faculty of Health, University of Witten-Herdecke,
Witten, Germany
Thomas Fru¨hwald, MD: Hietzing Hospital and Neuro-
logical Center Rosenhu¨gel, Wolkersbergenstraße 1, 1130
Vienna, Austria
Christoph Gisinger, MD: Haus der Barmherzigkeit,
Danube University Krems, Seebo¨ckgasse 30a, 1160
Vienna, Austria
Manfred Gogol, MD: Lindenbrunn Hospital, Geriatric
Department, Lindenbrunn 1, 31863 Coppenbruegge,
Germany
Markus Gosch, MD: Regional Hospital Hochzirl, Anna-
Dengel House, 6170 Zirl, Austria
Hans Gutzmann, MD: Hedwigsho¨he Hospital, Clinic for
Psychiatry, Psychotherapy and Psychosomatic Medicine,
Ho¨hensteig 1, 12526 Berlin, Germany
Isabella Heuser, MD: Charite´ University Hospital Ber-
lin, Department of Psychiatry and Psychotherapy, Univer-
sity Medicine Berlin, Campus Benjamin Franklin,
Eschenallee 3, 14050 Berlin, Germany
Werner Hofmann, MD: Friedrich Ebert Hospital, Clinic
for Geriatric Medicine, Friesenstrasse 11, 24534 Neumu-
enster, Germany
Michael Hu¨ll, MD: Center for Geriatric Medicine and
Gerontology Freiburg, University Clinic Freiburg, Lehener
Straße 88, 79106 Freiburg, Germany
Bernhard Iglseder, MD: Department of Geriatric Med-
icine, Christian-Doppler-Klinik, Paracelsus Medical Uni-
versity, Ignaz-Harrer-Str. 79, 5020 Salzburg, Austria
Anja Kwetkat, MD: Jena University Hospital, Depart-
ment of Geriatric Medicine, Bachstraße 18, 07743 Jena,
Germany
Michael Meisel, MD: Deaconess Hospital Dessau,
Clinic for Internal and Geriatric Medicine, Gropiusallee 3,
06846 Dessau, Germany
Wolfgang Mu¨hlberg, MD: Clinic for Internal Medicine 4
– Geriatric Medicine, Frankfurt Ho¨chst Hospital, Gote-
nstraße 6-8, 65929 Frankfurt am Main, Germany
Wolfgang von Renteln-Kruse, MD: Albertinen Hospital/
Albertinen House, non-profit company (GmbH), Center for
Geriatric Medicine and Gerontology, Scientific Institution
at the University of Hamburg, Sellhopsweg 18-22, 22459
Hamburg, Germany
Regina Roller, MD: Medical University of Graz,
Department of Internal Medicine, Auenbruggerplatz 15,
8036 Graz, Austria
Ralf-Joachim Schulz, MD: Geriatric Clinic at the St.-
Marien Hospital, Kunibertkloster 11-13, 50668 Ko¨ln,
Germany
Ulrike Sommeregger, MD: Hietzing Hospital and Neu-
rological Center Rosenhu¨gel, Wolkersbergenstraße 1, 1130
Vienna, Austria.
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